Document Detail


Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
MedLine Citation:
PMID:  23296156     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Antibody-dependent cellular cytotoxicity (ADCC), which is activated by effector cells via immunoglobulin G (IgG) fragment C receptors (FcRs), was proposed as a mechanism of cetuximab efficacy. Peripheral blood mononuclear cells (PBMCs) from 23 healthy donors and 13 patients with metastatic colorectal cancer (mCRC) treated with cetuximab were tested for FcγR polymorphisms and cetuximab-mediated ADCC. ADCC was measured by chromium-51 release on a epidermal growth factor receptor (EGFR)-positive human colon cancer cell line. Overall, 86 mCRC patients were genotyped for study purposes. PBMCs harbouring the FcγRIIIa 158 V/V genotype had a significantly higher cetuximab-mediated ADCC. No correlation was found between FcγR polymorphisms and response rate or time to progression after cetuximab-based therapy. Despite the in vitro analysis showing that the FcγRIIIa 158 V/V genotype is associated with higher ADCC, clinical data do not support a predictive role of FcγRIIIa polymorphisms in mCRC treated with cetuximab.The Pharmacogenomics Journal advance online publication, 8 January 2013; doi:10.1038/tpj.2012.54.
Authors:
F V Negri; A Musolino; N Naldi; B Bortesi; G Missale; D Laccabue; A Zerbini; R Camisa; N Chernyschova; G Bisagni; F Loupakis; A Ruzzo; T M Neri; A Ardizzoni
Related Documents :
21400506 - Family history of cancer and the risk of laryngeal cancer: a case-control study from it...
23026566 - Detection of human telomerase reverse transcriptase mrna in cells obtained by lavage of...
23958396 - Evading apoptosis in cancer.
24575976 - Gemcitabine resistance is associated with epithelial-mesenchymal transition and inducti...
21400506 - Family history of cancer and the risk of laryngeal cancer: a case-control study from it...
21630056 - Can patients with metastatic breast cancer be cured after introduction of newer and mor...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-08
Journal Detail:
Title:  The pharmacogenomics journal     Volume:  -     ISSN:  1473-1150     ISO Abbreviation:  Pharmacogenomics J.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101083949     Medline TA:  Pharmacogenomics J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Medical Oncology Unit and Medical Genetics Unit, University Hospital of Parma, Parma, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Experiences of Weight Stigmatization: A Review of Self-Report Assessment Measures.
Next Document:  Doctor-certified sickness absence in first and second trimesters of pregnancy among native and immig...